Search Within

Monica Chen

Formats
  1. Meeting Abstract (15)
  2. Journal Article (10)
  3. Review (3)
  4. Editorial (2)
  5. Research Letter (2)
  6. Correspondence (1)
Groups
  1. GME, Medicine (33)
  2. Graduate Medical Education (33)
  3. Hematology-Oncology Fellows (33)
  4. Melanoma Disease Management Team (33)
  5. Weinberg Fellows (33)
  6. Department of Medicine (32)

More Groups

People
  1. Alexander Drilon (17)
  2. Mark Kris (13)
  3. Helena Yu (10)
  4. Clare Wilhelm (7)
  5. Soo Ryum Yang (7)
  6. Guilherme Harada (6)

More People

Years
  1. 2025 (6)
  2. 2024 (15)
  3. 2023 (12)
Publications
  1. Journal of Clinical Oncology (9)
  2. Journal of Thoracic Oncology (7)
  3. JCO Precision Oncology (4)
  4. Annals of Oncology (3)
  5. JAMA Oncology (2)
  6. Annual Review of Cancer Biology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (13)
  2. Elsevier Inc. (7)
  3. Oxford University Press (3)
  4. American Association for Cancer Research (2)
  5. American Medical Association (2)
  6. Adis International Ltd (1)

More Publishers

Results (33)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma
    Meeting Abstract

    Smithy, J. W.; Momtaz, P.; Shoushtari, A. N.; Das, J. P.; Lezcano, C.; Nair, S.; Lochrin, S. E.; Chen, M. F.; Panageas, K.; Postow, M. A.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease
    Meeting Abstract

    Yu, H. A.; Chen, M. F.; Hui, A. B.; Choudhury, N. J.; Lee, J. J. K.; Zheng, J.; Ahn, L. S. H.; Pupo, A.; Nesselbush, M.; Jabara, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Standardizing radiologic reporting of response to improve the patient experience: Comparing response categories of RECIST 1.1 and a novel, real-world, standardized, oncologic response lexicon derived from clinical radiology reports
    Meeting Abstract

    Chen, M. F.; Ma, W.; Caravella, B. A.; Harada, G.; Gangai, N.; Grimaldi, G.; Waksmundzki, A.; Trevenen, W.; Kohlasch, K.; Reynolds, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations
    Meeting Abstract

    Chen, M. F.; Rakhade, S.; Quintanal-Villalonga, A.; Lee, J.; Forsythe, B.; Moses, K. A.; Ahn, L. S. H.; Pupo, A.; Falcon, C. J.; Rekhtman, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Signatures of early plasticity in the histological transformation of lung cancer
    Meeting Abstract

    Rakhade, S.; Chen, M. F.; Quintanal-Villalonga, A.; Sabet, A.; Manoj, P.; Chaudhary, O.; Xu, T.; Masilionis, I.; Falcon, C. J.; Egger, J. V.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Basket trials: Past, present, and future
    Review

    Murciano-Goroff, Y. R.; Uppal, M.; Chen, M.; Harada, G.; Schram, A. M.
    Annual Review of Cancer Biology (2024)

    Fulltext@MSK | Save
  • Serial cell-free DNA sequencing in ROS1 fusion-positive lung cancers during treatment with entrectinib
    Journal Article

    Choudhury, N. J.; Woo, H. J.; Chen, M.; Shah, R.; Donoghue, M.; Berger, M.; Drilon, A.
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • Phase II study of osimertinib in patients with epidermal growth factor receptor mutations: Results from the NCI-MATCH ECOG-ACRIN (EAY131) trial subprotocol E
    Journal Article

    Chen, M. F.; Song, Z.; Yu, H. A.; Sequist, L. V.; Lovly, C. M.; Mitchell, E. P.; Moscow, J. A.; Gray, R. J.; Wang, V.; McShane, L. M.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors
    Journal Article

    Pecci, F.; Nakazawa, S.; Ricciuti, B.; Harada, G.; Lee, J. K.; Alessi, J. V.; Barrichello, A.; Vaz, V. R.; Lamberti, G.; Di Federico, A.; more...
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • POSing the question: MARIPOSA-2, do the ends justify the means?
    Editorial

    Chen, M. F.; Piotrowska, Z.; Yu, H. A.
    Annals of Oncology (2024)

    Fulltext@MSK | Save